Business Context and Reporting Period
Company: BridgeBio Pharma, Inc.
Filing Type: Form 8-K (Current Report)
Date: March 4, 2020
Event: Item 8.01 - Other Events (Credit Agreement Amendment)
BridgeBio Pharma, Inc. announced a commitment from Hercules Capital, Inc. to amend its existing Loan and Security Agreement. The filing details proposed terms for new capital commitments, interest rate adjustments, and maturity extensions.
Key Financial Metrics and Debt Structure
The filing focuses on debt restructuring and liquidity enhancement rather than operational financial results (revenue, profit, or cash flow are not reported in this document).
- Existing Outstanding Loan: $75,000,000
- Proposed New Loan Commitment: $125,000,000 total, structured as follows:
- Tranche IV: $25,000,000 (discretionary, fully available)
- Tranche V: $25,000,000 (immediately available)
- Tranche VI: $25,000,000 (milestone-based)
- Additional Discretionary Tranche: $50,000,000
- Total Proposed Commitments: $200,000,000
- Interest Rate Floors (New Loans): Greater of floating prime rate + margin or 8.15% (floor of 8.15%).
- End of Term Charge: 5.95% on the funded amount of the new loan commitment.
- Amendment Fee: 0.25% of the new loan commitment due at closing.
Material Changes Versus Prior Period
The proposed amendment introduces significant changes to the existing credit facility terms:
- Capital Increase: Total commitments would increase from $75,000,000 to $200,000,000.
- Maturity Extension: Maturity date extended up to 48 months from the amendment closing.
- Interest-Only Period: Extended up to 36 months from the amendment closing.
- Interest Rate Reductions:
- Tranche III ($20M): Rate reduced from a floor of 9.10% to 8.85%.
- Existing Term Loan ($35M): Rate reduced from a floor of 9.35% to 8.75% (if Tranche IV is drawn).
- Covenants:
- Subsidiaries may be added as co-borrowers/guarantors if draws exceed $75,000,000.
- Minimum unrestricted capital requirement of $35,000,000 applies if draws exceed $100,000,000 (subject to waivers based on milestones, market cap, or FDA approval).
Guidance, Outlook, and Risks
Management Commentary and Conditions: The filing states there can be no assurance that the Credit Agreement Amendment will become effective on the described terms or at all. The amendment is concurrent with an offering of convertible notes.
Risks and Contingencies:
- Prepayment Penalties: Charges of 2.50% (Year 1), 1.50% (Year 2), and 1.00% (Year 3+) apply to early prepayments.
- Liquidity Covenants: Strict minimum cash requirements ($35M) trigger upon significant draws, though these can be waived if the company achieves a $1 billion market capitalization or receives FDA approval for AG10.
- Collateral: Additional liens on intellectual property and assets of subsidiaries may be required if borrowing exceeds $75,000,000.
Investor Verification Checklist
- Confirm whether the Credit Agreement Amendment has officially closed and become effective.
- Verify the actual drawdown amounts of Tranches IV, V, and VI.
- Monitor the company's market capitalization to determine if the $35M minimum cash covenant is waived.
- Track progress toward FDA approval for AG10, which would permanently eliminate the minimum cash requirement.
- Review the terms of the concurrently announced convertible notes offering.